Study: Melting Glaciers could cause more volcanic eruptions
The loss of ice from the rapid glacial melting releases pressure on magma chambers underground and could cause volcanic eruptions to become more frequent and intense, the study, presented at the Goldschmidt Conference in Prague, said.
"As glaciers retreat due to climate change, our findings suggest these volcanoes go on to erupt more frequently and more explosively," Lead researcher at the University of Wisconsin-Madison, Pablo Moreno, said.
The study placed six volcanoes in Chile under crystal analysis to determine how the shifting of the Patagonia Ice Sheet impacted the strength and frequency of previous volcanic eruptions.
Studies linking the impacts of climate change on volcanic eruptions had previously been conducted in Iceland, but the latest study was the first to assess the links to continental volcanic systems.
"Our study suggests this phenomenon isn't limited to Iceland, where increased volcanic activity has been observed, but could also occur in Antarctica," said Moreno. "Other continental regions, like parts of North America, New Zealand, and Russia, also now warrant closer scientific attention,"
"We found that following deglaciation, the volcano starts to erupt way more, and also changes composition," said Moreno. The composition changed as the magma melted crustal rocks while eruptions were suppressed. This made the molten rock more viscous and more explosive on eruption.
Scientists found that during the last ice age, thick ice covered and suppressed the number of eruptions. Then, as the Earth heated up, volcanic activity increased by two to six times.
"Glaciers tend to suppress the volume of eruptions from the volcanoes beneath them. But as glaciers retreat due to climate change, our findings suggest these volcanoes go on to erupt more frequently and more explosively," said Dr Moreno. "The key requirement for increased explosive is initially having a very thick glacial coverage over a magma chamber, and the trigger point is when these glaciers start to retreat, releasing pressure, which is currently happening in places like Antarctica."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
UPI
17 hours ago
- UPI
You might inhale ight Inhale 68,000 microplastics per day
The French team used high tech equipment to measure concentrations of microplastics in 16 air samples from their own apartments and cars. Photo by Adobe Stock/HealthDay July 31 (UPI) -- Scientists say the average person may be inhaling microscopic, lung-penetrating plastic particles at a rate that's 100 times what was previously assumed: 68,000 per day. "Everywhere we look, we find microplastics, even in the air we breathe inside our homes and cars," said the French team that conducted the study. "The biggest concern is how small these particles are, completely invisible to the naked eye. We inhale thousands of them every day without even realizing it." The study was led by Nadiia Yakovenko of the University of Toulouse and published July 30 in the journal PLOS One. As the researchers noted, prior research has sought to estimate how many microplastics people breathe in daily. But those studies focused on relatively large particles -- about 20 to 200 micrometers in diameter. Yakovenko's team tracked even more minute plastic particles, ranging from 1 to 10 micrometers across - far smaller than a human hair. Their incredibly small size means these invaders can penetrate deep into the lungs. The French team used high tech equipment to measure concentrations of microplastics in 16 air samples from their own apartments and cars. They found that in their apartments, an average of 528 microplastic particles per cubic meter floated in the air they breathed. That rose to 2,238 particles per cubic meter for car interiors, tested under normal driving conditions. Most (94%) of these particles were very tiny -- between 1 to 10 micrometers in diameter. Yakovenko's team estimated that people breathe in 3,200 larger (10 to 300 micrometers in diameter) microplastic particles per day and 68,000 smaller ones (1 to 10 micrometers). The findings point to "indoor air as a major and previously underestimated exposure route of fine particulate microplastic inhalation," the researchers said. Just how harmful are these microplastics? The jury is still out on that. However, in a study presented in April at a meeting in Chicago of the American College of Cardiology, researchers from Case Western Reserve School of Medicine in Cleveland reported that high blood pressure, diabetes and stroke rates are higher in coastal or lakefront areas of the U.S. with greater concentrations of microplastics in the environment. Research presented at meetings is typically considered preliminary, until published in a peer-reviewed journal. Microplastics might even be harming the brain. In a study published in 2024, researchers in Germany and Brazil found that 8 of 15 autopsied adults had microplastics detected within their brain's smell centers, the olfactory bulb. Particles have also been detected in human lungs, intestines, liver, blood and testicles, and even in semen. More information Find out more about microplastics at Stanford University. Copyright © 2025 HealthDay. All rights reserved.
UPI
21 hours ago
- UPI
Larger statin dosages urged for many with cholesterol, heart risks
1 of 2 | Dr. Charles Hennekens, a medical school professor and heart disease researcher at Florida Atlantic University in Boca Raton, Fla., says too many patients at high risk of heart attacks and stroke are being "underdosed" with beneficial statin drugs. Photo by Alex Dolce, Florida Atlantic University ST. PAUL, Minn., July 31 (UPI) -- Doctors are routinely "underdosing" statins for patients at risk for heart attacks and strokes due to elevated levels of "bad" cholesterol, even though the drugs have proven safe and effective, a top U.S. researcher maintains. At a time when an estimated 40% of U.S. adults have metabolic syndrome -- a combination of heart risk factors including obesity, hypertension, dyslipidemia and insulin resistance -- doctors usually don't start them off with the maximum dosage of statins, even though they can quickly lower levels of LDL cholesterol, according to an opinion published this month in the medical journal Trends in Cardiovascular Medicine. Co-author Dr. Charles Hennekens, the Sir Richard Doll Professor of Medicine and Preventive Medicine at Florida Atlantic University's Charles E. Schmidt College of Medicine in Boca Raton, says his analysis of several major clinical studies of the new generation of highly potent statins, such as rosuvastatin and atorvastatin, shows that maximal doses are safe and sorely needed, but aren't being prescribed. Those with metabolic syndrome have cardiovascular risks equivalent to those with prior heart attacks or strokes, yet many are "undertreated" by starting their statin regimens at low or moderate dosages, Hennekens told UPI. "The data indicate that over half of people who were put on a statin remain on the initial dose they're given, so even though the intent may be to titrate it up, it's not done in the majority of instances," he said. "So, you get on a low dose of statin and you stay on it." But this "flies at the face of the data" showing that statins "have the strongest and most consistent body of evidence supporting their prescription in treatment and prevention in both men and women including older adults," he said. "There's no threshold for LDL below which you don't see incremental benefits." The studies demonstrate newer statins can lower LDL, or bad cholesterol, in as quickly as a month and can provide related benefits, such as stabilizing the build-up of harmful plaque on the cells that line the interior surface of blood vessels, Hennekens said. Therefore, he urges cardiologists who initiate drug therapies for those with metabolic syndrome to start statins at maximal tolerated levels. "Everything points to getting on the highest dose of evidence-based statin," he noted. "The goal of LDL in the high-risk secondary patients is less than 50 [milligrams per deciliter], and we have a lot to do to achieve that goal because there are lots of forces in society, especially in American society, that are making that more difficult. "For example, in the United States today, in middle-age people gain 7 to 10 pounds of body weight every 10 years, so we have a society that's fatter, but only about 21% of Americans reach the daily minimum recommendation for daily physical activity, Hennekens said. "We have a nation that would benefit enormously from therapeutic lifestyle changes, but in the end, we have such high absolute risk that many are going to require adjunctive therapy." And if so, "we make a strong case that the first one you should consider is a statin, and that every other adjunctive therapy should be viewed in the context of residual risk after the statin is given with maximal doses," Hennekens added. Other experts on the use of statins to control LDL cholesterol contacted by UPI generally agreed with the premise that dosages should start at maximum levels for those at high risk of heart disease. Dr. Laurence Sperling, the Katz Professor in Preventive Cardiology at the Emory University School of Medicine in Atlanta, noted it's already on a list of guidelines developed in 2018 by an American College of Cardiology/American Heart Association joint task force. "In patients with clinical atherosclerotic cardiovascular disease, [the guidelines say] reduce LDL cholesterol with high-intensity statin therapy or maximally tolerated statin therapy," he said. "The more LDL cholesterol is reduced on statin therapy, the greater will be subsequent risk reduction." Sperling said he agreed with the recommendation to use "a maximally tolerated statin to lower LDL-C levels by 50%." Joseph Saseen, a researcher and professor of clinical pharmacy at the University of Colorado's Skaggs School of Pharmacy and Pharmaceutical Sciences in Boulder, told UPI one reason for the low-dosage prescriptions is that cardiologists overestimate the chances of possible side effects, such as muscle aches and digestive problems. "While dose-related side effects can occur, they do not justify the routine underdosing of statins in high-risk populations," Saseen said. "Clinicians too often initiate therapy at suboptimal doses, particularly in patients with elevated [cardiovascular] risk. Evidence-based guidelines recommend starting high-intensity statin therapy, especially very high-risk secondary prevention patients." Clinical data have shown, for instance, that initiating atorvastatin at as much as 80 mg. daily "is both safe and effective in reducing cardiovascular events among secondary prevention patients," Saseen said. "Similarly, rosuvastatin at 20 mg. has been shown to be a safe and effective starting dose in primary prevention patients with elevated [high-sensitivity C-reactive protein]." Also agreeing with Hennekens' conclusion is Dr. Paul Heidenreich, a practicing cardiologist, professor at the Stanford University School of Medicine and chief of medicine at the Palo Alto, Calif., Veterans Affairs clinic. "When high intensity statins are indicated, one can recommend starting with the high intensity or beginning with moderate intensity followed by up-titration," he said. He noted some cardiologists are concerned that if patients can't tolerate a high-intensity statin, they may subsequently refuse all statins, in which case it may be better to start off with a moderate dose. "However, I feel it is rare that the patient will refuse to try a lower dose," Heidenreich said. "As the authors note, titration to a higher intensity is not as frequent as it should be, with patients staying on the initial intensity. Thus, patients are likely better off starting with the recommended high-intensity statin." The clinical data also showed that the rate of intolerance with a placebo "was surprisingly high, suggesting that patients are on the lookout for any new symptom that occurs following initiation of a new medication. It is important to stress that the vast majority of patients tolerate statins medications without side effects," he said.
UPI
a day ago
- UPI
SpaceX Crew-11 set for launch to ISS
1 of 4 | SpaceX's Crew-11 mission will launch to the International Space Station on Thursday. Photo by Pat Benic/UPI | License Photo July 31 (UPI) -- SpaceX's Crew-11 is set to launch from Florida to the International Space Station on Thursday afternoon. The mission is scheduled for 12:09 p.m. EDT from Launch Complex 39A at Kennedy Space Center aboard a Falcon 9 Rocket. "I'm so eager to see this mission launch, but as always, we launch when we're ready. With a little luck, we'll see a launch soon, and we'll also see a crew come home soon," said Ken Bowersox, associate administrator for NASA's Space Operations Mission Directorate, during a prelaunch briefing. "But be patient with us. Let's make sure that the vehicle is ready to go and that our team is really certain before we hit the button." Crew-11 astronauts Zena Cardman, Mike Fincke, Kimiya Yui and Oleg Platonov will take 39 hours to reach the ISS. Arrival time is estimated at 3 a.m. on Aug 2. "We'll watch that time closely. We have a limit of about 40 hours or so of ability to sustain the crew on the way to station when we protect all the consumables for contingencies. So, we'll watch that really carefully," said Steve Stich, manager of NASA's Commercial Crew Program. Cardman, commander of Crew-11 in a press briefing said six-month stays on the ISS will help prepare NASA to send astronauts much deeper into space. "Understanding how to live and work for long durations -- going and staying -- is a really interesting challenge, and I'm grateful that we've gotten the chance to do this -- to hone our skills on the ISS, so that we can do this for longer durations on the moon," Cardman said. According to NASA there is a full schedule of experiments and maintenance tasks when the crew is on the ISS. They will investigate the additive manufacturing process for small metal parts in microgravity and will look at physiological and psychological changes that happen across mission durations to prepare for a three-year journey to Mars. "This studies how astronauts adapt to space over different mission durations, integrating multidisciplinary research to assess physiological and psychological changes that develop and really to develop those countermeasures that are critical for us to go to the longer-duration missions, like a three-year mission to Mars, if you can imagine," Spetch said during the press conference. Crew-10 and Crew-11 will be working together before the Crew-10 team returns to Earth on Aug 6.
